HomeAI · summaries
Storia in 5 fonti
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
- ·
investors.com
Biotech Plummets On Cancer Disappointment. What Happened?
Celcuity stock crashed Tuesday on disappointing results for its three-drug approach to advanced breast cancer.
- ·
endpoints.news
Celcuity aims for broad FDA approval after positive breast cancer readout
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.
- ·
benzinga.com
What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.
- ·
medpagetoday.com
PAM Inhibitor Doubles Time to Progression in Advanced Breast Cancer Subset
Novel gedatolisib is currently under review at FDA for wild-type patients